PMVP — PMV Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1699382 ·
Last close
$1.30
Market Cap
$69.76M
52W High
$1.45
52W Low
$1.03
ADV30
314,008
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -19,019,000 | -18,038,000 | 96,562,000 | 39,130,000 | 8,595,000 |
| Dec 2025 | 0 | — | -19,242,000 | -18,037,000 | 116,562,000 | 37,983,000 | 11,850,000 |
| Sep 2025 | 0 | — | -22,522,000 | -21,059,000 | 133,844,000 | 36,337,000 | 12,845,000 |
| Jun 2025 | 0 | — | -22,879,000 | -21,210,000 | 152,855,000 | 44,127,000 | 12,250,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-74,990,000
Investing CF
$62,282,000
Financing CF
$495,000
CapEx
$-86,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.49
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,492,000
Inventory
—
Receivables
—
ST Investments
$54,419,000
EBIT TTM
$-83,662,000
Pretax Income TTM
$-78,319,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -86,206,000 | -77,742,000 | 116,562,000 | 11,850,000 | — | -73,577,000 |
| Dec 2024 | 0 | -85,448,000 | -58,709,000 | 191,288,000 | 15,208,000 | — | -51,282,000 |
| Dec 2023 | 0 | -80,132,000 | -68,960,000 | 252,152,000 | 26,463,000 | — | -55,657,000 |
| Dec 2022 | 0 | -77,040,000 | -73,317,000 | 270,308,000 | 24,280,000 | — | -63,760,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.15
Max Pain — expiry 2026-10-16
max pain strike: $2.50 · spot: $1.30 · call oi: 1,092 · put oi: 10
Expected Move to 2026-10-16:
±$2.60
(199.23%) —
implied range
$-1.30 –
$3.90
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TENX | TENAX THERAPEUTICS, INC. | $69.23M | $1.85 | — |
| XBIT | XBiotech Inc. | $70.43M | $2.31 | — |
| RNTX | Rein Therapeutics, Inc. | $69.01M | $0.80 | — |
| IBIO | iBio, Inc. | $70.54M | $1.42 | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $70.59M | $1.14 | — |
News headlines (Yahoo Finance, 1h cache)
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-14 12:00 · Yahoo
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-06-10 13:35 · Yahoo
Why PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial Activity
2026-06-02 13:56 · Yahoo
PMV Pharmaceuticals Announces Board Chair Transition
2026-04-22 12:00 · Yahoo
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?
2026-08-19 16:00 · Yahoo
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
2026-06-24 16:00 · Yahoo
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-12 12:00 · Yahoo
12 Health Care Stocks Moving In Wednesday's After-Market Session
2026-05-13 21:06 · Yahoo
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?
2026-04-20 18:34 · Yahoo
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
2026-03-06 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.